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Introduction 
Professionals within clinical practice frequently encounter patients hospitalized with acute heart 
failure (AHF).
1-5
 These patients commonly present with signs and symptoms of congestion, but some 
patients also present with signs of tissue hypoperfusion contributing to impaired organ function.
6
 
Regardless of their clinical profile or type of heart failure (i.e. reduced or preserved ejection fraction
7
), 
comprehensive inpatient monitoring in conjunction with thorough physical examination is crucial to 
optimize management. Clinicians are under increasing pressure to keep inpatient length of stay as short as 
possible while also preventing post‐discharge emergency visits, rehospitalization and short‐term 
mortality. More effective monitoring might help to achieve these goals and improve the accuracy of 
discharge readiness assessments.  
 
The 2016 European Society of Cardiology (ESC) heart failure guidelines provide recommendations 
based on the available evidence for the inpatient management of AHF. It is notable that 17 of the 18 
recommendations related to monitoring, all class I recommendations, are rated as level of evidence C 
(‘consensus of opinion of the experts and/or small studies, retrospective studies, registries’) (Table 1).6 
Thus, a substantial evidence gap exists regarding the optimal inpatient monitoring strategies for these 
severely ill patients.  
  
Table 1. ESC guideline recommendations and further considerations for in‐hospital monitoring of patients with acute heart failure 
Topic Guideline recommendation6 
 
Diagnostic evaluation: baseline and initial monitoring; usually in emergency department or at point of initial admission 
Non‐invasive vital 
signs 
Standard non‐invasive monitoring of heart rate, rhythm, respiratory rate, oxygen saturation and blood 
pressure is recommended (class I, level of evidence C).  
Biomarkers Upon presentation, a measurement of plasma natriuretic peptide level (BNP, NT‐proBNP or MR‐proANP) is 
recommended in all patients with acute dyspnoea and suspected AHF to help in the differentiation of AHF 
from non‐cardiac causes of acute dyspnoea (class I, level of evidence A).  
Electrocardiogram 12‐lead ECG is recommended at admission in all patients presenting with suspected AHF (class I, level of 
evidence C).  
Chest X‐ray Chest X‐ray is recommended at admission in all patients presenting with suspected AHF to assess signs of 
pulmonary congestion and detect other cardiac or non‐cardiac diseases that may cause or contribute to the 
patient's symptoms (class I, level of evidence C).  
Laboratory 
assessments 
Cardiac troponins, blood urea nitrogen, creatinine, electrolytes (sodium, potassium), glucose, complete blood 
count, liver function tests, and thyroid stimulating hormone are recommended at admission in all patients 
presenting with suspected AHF (class I, level of evidence C).  
Echocardiography Echocardiography is recommended immediately in haemodynamically unstable AHF patients and within 
48 h when cardiac structure and function are either not known or may have changed since previous studies 
(class I, level of evidence C).  
Clinical status monitoring: usually in intensive or critical care unit; less invasive components of monitoring  continued on the 
general ward or prior to discharge 
Vital signs Standard non‐invasive monitoring of heart rate, rhythm, respiratory rate, oxygen saturation and blood 
pressure is recommended (class I, level of evidence C).  
Body weight and fluid 
balance 
It is recommended that patients should be weighed daily and have an accurate fluid balance chart completed. 
This includes accurate measurements of urine output in critically ill patients (class I, level of evidence C).  
Signs and symptoms It is recommended to evaluate signs and symptoms relevant to heart failure (e.g. dyspnoea, pulmonary rales, 
peripheral oedema, weight) (class I, level of evidence C).  
Laboratory 
assessment 
Frequent, often daily measurement of renal function (blood urea, creatinine) and electrolytes (potassium, 
sodium) during i.v. therapy and when renin–angiotensin–aldosterone system antagonists are initiated is 
recommended (class I, level of evidence C).  
Invasive monitoring Invasive monitoring with an arterial line is recommended in patients with cardiogenic shock (class I, level of 
evidence C).  
Intra‐arterial line should be considered in patients with hypotension and persistent symptoms despite 
treatment (class IIa, level of evidence C).  
Pulmonary artery catheter may be considered in patients who, despite pharmacological treatment, present 
refractory symptoms (particularly with hypotension and hypoperfusion) (class IIb, level of evidence C).  
Oxygenation Transcutaneous monitoring of arterial oxygen saturation is recommended (class I, level of evidence C).  
Blood gas analysis Measurement of blood pH and carbon dioxide tension (possibly including lactate) should be considered, 
especially in patients with acute pulmonary oedema or history of COPD using venous blood. In patients with 
cardiogenic shock, arterial blood is preferable (class IIa, level of evidence C).  
  
 
AHF, acute heart failure; BNP, B‐type natriuretic peptide; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; 
NT‐proBNP, N‐terminal pro B‐type natriuretic peptide; MR‐proANP, mid‐regional pro‐atrial natriuretic peptide. 
Despite this lack of evidence, physicians are expected to deploy the best monitoring tools to guide 
management decisions for their patients. Importantly, monitoring is a dynamic process involving a 
spectrum of different clinical, biochemical and physiological parameters. These variables should be 
interpreted in the context of the whole patient, rather than as isolated measurements. Importantly, equal 
attention should be paid to changes in measurements over time. Moreover, the feasibility, costs, and 
possible harms of monitoring, as well as the required knowledge and skills for appropriate use of 
monitoring tools should be considered when optimizing monitoring approaches for an individual patient. 
This document provides the multidisciplinary team with practical applications of guideline 
recommendations for the inpatient monitoring of patients with AHF (Figure 1). Recommendations that 
are taken from the ESC guidelines are noted by reference and the description of the accompanying 
recommendation class and level of evidence. Practical suggestions for clinical application do not have an 
associated recommendation class or level of evidence. Identifying research priorities to address the gaps 
in evidence (Table 2) to improve the evidence base for future guideline recommendations is also 
addressed. 
 
 
 
Figure 1. Suggested inpatient monitoring for patients with acute heart failure. Comprehensive inpatient monitoring is crucial to the 
optimal management of acute heart failure patients. Many tools are available for in‐hospital monitoring of patients with acute heart 
failure, and each plays a role at various points throughout the patient's treatment course, including the emergency department, 
intensive care or coronary care unit, and the general ward. As a result of diverse precipitants, left ventricular end‐diastolic pressure 
(LVEDP) and natriuretic peptides (NPs) increase (red curve) and their elevation precedes worsening of congestion (black curve). 
This pattern may be useful to identify early subclinical decompensation. In spite of symptomatic improvement as a result of in‐
hospital therapies for a subset of patients, high LVEDP and NP values are still persistent during hospitalization and in the early post‐
discharge period, and identification of haemodynamic congestion is crucial for preventing early post‐discharge adverse events in 
these patients. Yellow arrows represent continuous monitoring; yellow boxes indicate suggested monitoring repeated at various time 
points. BP, blood pressure; cTn, cardiac troponin; ECG, electrocardiogram; ECHO, echocardiogram; GDMT, guideline‐directed 
medical therapy; HR, heart rate; IV, intravenous; RR, respiratory rate; SaO2, oxygen saturation. *Invasive BP monitoring and blood 
gases may be indicated in the intensive or coronary care unit and in most critical patients. †Continuous telemetry monitoring in 
selected patients. ‡In the de novo patient, oral GDMT is started stepwise when the patient is stabilized. In patients with worsening 
chronic heart failure, ongoing medications should be continued at the highest tolerated dose as appropriate for the clinical situation.  
 
  
Table 2. Gaps in knowledge and priorities for research 
Topic Research priorities 
  
Body weight, urine output, 
and fluid balance 
 Impact of daily weight and fluid balance monitoring 
 Quantify and validate definition for diuretic responsiveness (e.g. urine sodium loss) vs. 
diuretic resistance  
Electrolytes  Normalization of serum sodium during hospitalization 
 Guiding diuretics or alternative treatment (e.g. haemofiltration) based on electrolytes 
(particularly sodium and chloride)  
Markers of kidney function  Prospectively test decongestive strategies guided by kidney biomarker profiles 
 Evaluate the impact of various strategies (i.e. primarily vasodilator‐based vs. primarily 
diuretic‐based) on kidney marker profiles and clinical outcomes  
 Examine pathophysiology of serum creatinine increases in the context of decongestion 
 Identify and validate new kidney markers for accurate reflection of renal function in acute 
settings  
Liver function  Assess utility of liver function markers to evaluate decongestion and guide treatment 
decisions  
 Prospectively test whether markers of cholestasis (reflecting congestion) and/or markers of 
hypoxic hepatitis (reflecting hypoperfusion) offer additional prognostic and therapeutic 
information to clinical evaluation  
Cardiac biomarkers  Validate the multimarker approach for informing diagnosis and prognosis 
 Establish the incremental value of a multimarker approach, including the combination of 
biomarkers with imaging markers  
 Identify markers of low‐risk that can facilitate safe early discharge from the emergency 
department or hospital  
 Identify biomarkers to guide therapy selection (i.e. precision medicine) or monitor response 
to therapy and improve patient outcome  
Rhythm monitoring  Delineate which patients need continuous ECG monitoring 
 Validate risk prediction tools (e.g. scores, biomarkers, clinical assessment, history, or a 
combination of these) used to triage patients for ‘high‐intensity inpatient monitoring’ or 
‘low‐intensity inpatient monitoring’  
Echocardiography  Determine the best indices of elevated LAP 
 Evaluate using LAP indices or cardiac output to guide decongestive therapy 
 Identify echocardiography findings that indicate a need for inotropic support 
 Determine criteria that indicate failure of medical therapy and need for mechanical support  
Lung ultrasound  Evaluate lung ultrasound (i.e. changes in the quantity of B‐lines) to guide decongestive 
therapy  
 Determine utility of lung ultrasound to indicate discharge readiness 
 Directly compare B‐lines with chest X‐ray 
Non‐invasive monitoring  Validate thoracic bioimpedance to assess volume responsiveness and central haemodynamic 
response to physiological and pharmacological stimulation  
 Identify target values for microvascular flow 
 Determine how therapeutic interventions could be tailored to microvascular flow data 
 Evaluate the usefulness of microcirculation assessments for guiding treatment decisions 
 Comparison of direct vs. surrogate measurements of microcirculation 
Risk score  Externally validate risk stratification and prognostic scores 
 Evaluate generalizability of scores 
 Determine whether application of risk scores improves patient outcome (i.e. through better 
risk stratification, application of appropriate therapies or better health care utilization)  
  
 
AHF, acute heart failure; ECG, electrocardiogram; LAP, left atrial pressure. 
  
Clinical monitoring 
Overview 
Congestion is present in >90% of patients and is the leading cause of hospitalization in patients with 
AHF.
6,8,9
 Most patients present as ‘wet and warm’ with normal or elevated blood pressure and adequate 
perfusion, symptoms (e.g. dyspneoa, orthopnoea, breathlessness on minimal exertion, abdominal 
discomfort, or loss of appetite), and signs (e.g. pulmonary rales, oedema, elevated jugular venous 
pressure, hepatomegaly, ascites) of congestion due to either volume overload or fluid redistribution.
6
 
Since a single clinical symptom or sign may lack sensitivity or specificity, clinical decisions should be 
based on comprehensive evaluation of all findings.
10
 Congestion in the setting of AHF is also associated 
with organ dysfunction and poor prognosis
.11-13
 Far fewer patients present with symptoms or clinical signs 
of hypoperfusion or cardiogenic shock (e.g. cool sweaty extremities, oliguria, mental confusion, 
dizziness, hypotension, narrow pulse pressure), but these situations require urgent interventions to be 
taken to prevent ensuing death.
14
 In the ESC Heart Failure Long‐Term Registry, 70% presented with 
congestion without hypoperfusion, 13.6% with congestion and hypoperfusion, and 0.9% with 
hypoperfusion without congestion.
15 
 
The clinical picture may be more dramatic in new‐onset, acute de novo patients than in patients with 
chronic heart failure who present with gradually worsening dyspnoea. In the EuroHeart Failure Survey II, 
the prevalence of pulmonary oedema was 26% in patients with de novo AHF and 10.4% in patients with 
acutely decompensated chronic heart failure. Cardiogenic shock occurred in 6.8% of acute de novo heart 
failure patients and in 2.2% of acutely decompensated chronic heart failure patients.
8 
 
The initial primary therapeutic objectives in AHF are the control of symptoms and relief of congestion 
and fluid overload while preventing further organ injury.
6,13
 The ESC guidelines recommend daily 
assessment of weight and accurate fluid balance charting.
6,16
 While perhaps intuitive, data are scarce 
linking these practices with improved management or outcome.  
Non‐invasive vital sign monitoring 
In accordance with the ESC guidelines, non‐invasive monitoring of blood pressure, respiratory rate, 
and pulse oximetry should be performed at the time of initial presentation (class I, level of evidence 
C).
6,17
 Although not specified in the guidelines, these measurements should be repeated at intervals based 
on the changing clinical status of the patient. Rapid changes in vital signs may indicate multi‐organ 
injury.
13
 For those more severely ill or with a very dynamic clinical profile, this may be every 15 min. In 
those patients whose profile changes gradually and who are less severely ill, this could be as infrequent as 
three times daily. Of note, recent advances in pulse oximetry technology may provide broader 
information, including perfusion index and some indirect indices of cardiac output,
18 
but more research is 
needed.  
Body weight, urine output, and fluid balance 
Monitoring weight change and targeting a negative net fluid balance assumes that congestion is 
always accompanied by fluid overload and weight gain. However, as many as 50% of patients with AHF 
are hospitalized without significant weight gain in the days to weeks before presentation.
19-21
 Pulmonary 
congestion, manifested as a rise in left‐ and right‐sided filling pressures, often can occur without 
significant weight gain or even relative hypovolaemia through volume redistribution.
13,22,23
 Thus, first 
establishing the patient's volume phenotype (i.e. redistribution vs. overload recognizing there is overlap) 
is critical to facilitate the value of body weight monitoring. Nevertheless, it is reasonable to monitor 
weight (class I, level of evidence C) and targeting a specific euvolaemic weight may be appropriate in 
many patients. Weight gain that immediately precedes a hospitalization may help identify patients who 
have been non‐adherent to diet or medications, and reinforcement of education during the in‐hospital stay 
may be warranted for such patients. Weight gain in hospital is a predictor of 30‐day death or 
rehospitalization.
24 
 
Exact urine output measurement and accurate fluid charting are basic measures in intensive and 
cardiac care units. However, in regular wards these are more susceptible to errors. Moreover, calculation 
of net fluid balance should also include evaporation, which at best is an estimate. Exact and continuous 
measurement of urine output requires an indwelling urinary catheter, which is associated with patient 
discomfort, infection risk, and long‐term complications such as incontinence.6,17 The ESC guidelines do 
not recommend the routine use of a urinary catheter.
6
 Intensive care unit (ICU) patients are an exception 
in whom more intensive monitoring most often includes a more precise evaluation of urine output.  
 
In case of incontinence, weighing an incontinence pad
25
 or use of disposable urinary sheaths in 
males
26
 may be a better approach than estimation. Emerging data suggest that urinary characteristics (i.e. 
urine sodium excretion/mg loop diuretic administered) can indicate either diuretic efficiency since sodium 
content/urine volume tends to drop quickly during decongestion, or diuretic resistance.
27-29
 Other 
quantitative measures of diuretic response, such as weight or net fluid loss per unit of diuretic (e.g. per 40 
mg furosemide or equivalent), have also been proposed to assess response to decongestive therapy. There 
are no single cut‐offs for these indices; in general, the higher the values, the better the response. 
Haemoconcentration has also been proposed as a measure of decongestion.
30
 Poor diuretic response in 
patients with AHF has been associated with less symptom relief, in‐hospital worsening of heart failure, 
increased mortality, and higher rehospitalization rates.
28,31-33
 
Biomarker monitoring 
Arterial blood gas analysis and acid–base balance 
Arterial blood gas analysis provides vital information on oxygenation, ventilation, metabolic balance, 
an indication of tissue hypoxia. The selective use of these may assist with determining prognosis. It is 
usually performed on point of care analyzers measuring the partial pressures of oxygen (pO2), carbon 
dioxide (pCO2) and pH. Haemoglobin oxygen saturation (SpO2) can be either calculated or measured 
directly. Bicarbonate and base deficit/excess are derived values from pH and pCO2. Arterial blood gas 
analysis is generally restricted to patients with pulmonary oedema, severe AHF (on the verge of needing 
artificial ventilation), cardiogenic shock, or a history of chronic obstructive pulmonary disease (class IIa, 
level of evidence C) and can be obtained hourly as dictated by the patient's changing condition.
6 
 
Practical interpretation of arterial blood gas measurements consists of assessing pH and the respiratory 
and metabolic (i.e. base deficit/excess) components, calculating the anion gap in the presence of 
metabolic acidosis, and evaluating the primary disturbance and compensatory response. The most 
common acid–base imbalance in AHF is respiratory alkalosis, but metabolic acidosis, most often as a sign 
of poor end‐organ perfusion, has been associated with an increased mortality risk.34 Of note, both 
metabolic acidosis and alkalosis are associated with increased mortality.
35
 The prognostic value of 
admission pO2 and pCO2 remains controversial.
36
 The ratio of pO2/fraction of inspired oxygen gives a 
better impression of the adequacy of pulmonary gas exchange than pO2 alone. A high correlation has been 
demonstrated between pCO2 and pH measured in venous and arterial blood;
37,38
 thus, venous blood gas 
analysis is a very good alternative method, especially in those patients in whom pulse oximetry is over 
90%.  
 
The veno–arterial gradient in pCO2 measured in central lines can be used as a marker of tissue 
perfusion, although not specifically recommended in the ESC guidelines. Veno–arterial pCO2 gradient is 
affected by microvascular perfusion, as well as metabolism. As flow adapts to metabolism, an increased 
veno–arterial gradient in pCO2 (>6 mmHg) suggests that tissue perfusion is inadequate.
39
 An increased 
veno–arterial pCO2 gradient has been associated with poor outcome.
40  
Lactate 
Lactate, measured from either venous or arterial blood, is a very important indicator of tissue 
hypoperfusion. Elevated lactate levels may result from either excess production, impaired lactate 
clearance (e.g. liver dysfunction), or both. While lactate is often of anaerobic origin in the early hours 
after the onset of circulatory failure, other sources of lactate predominate at later stages.
41
 Hence, lactate 
is a good marker of tissue perfusion mostly in the early stages of circulatory failure. Elevations in lactate 
can cause metabolic acidosis, and lactic acidosis is a common cause of raised anion gap. Lactate 
concentrations >2 mmol/L are generally considered as abnormal and associated with higher mortality, but 
levels at the higher end of the normal reference range (>0.75 mmol/L) have also been associated with 
slightly increased mortality in patients admitted to the ICU.
42
 Furthermore, lactate levels that do not 
decrease following appropriate treatment are associated with a poor outcome.
43,44
 The optimal 
measurement intervals are not specifically described in the guidelines, but practically, lactate levels 
should be assessed in haemodynamically unstable or hypoxaemic patients with AHF at the time of 
admission and repeated at shorter intervals initially (e.g. every 1–2 h) during the acute phase of 
hospitalization. The lactate time interval can then be increased as the patient stabilizes.
44
 
Electrolytes 
Electrolytes should be routinely measured on admission in patients with AHF (class I, level of 
evidence C) together with serum creatinine and urea nitrogen (Table 1).
6
 During administration of 
vasoactive and diuretic therapy, electrolytes should be reassessed at least daily until discharge, 
particularly if intravenous loop diuretics are used, with more frequent testing if clinically indicated
6
 (e.g. 
with deteriorating renal function or initiation of renin–angiotensin–aldosterone system antagonists). 
Serum hyponatraemia at admission predicts poor prognosis in patients hospitalized for AHF.
45,46
 
Additional testing is needed to distinguish between depletional and dilutional hyponatraemia as this will 
guide further therapy.
47
 Hypo‐ or hyperkalaemia are associated with arrhythmias (e.g. QT prolongation, 
torsades de pointes, or other life‐threatening arrhythmias), and confirmed abnormal potassium levels 
should be corrected. Hypokalaemia as well as hypomagnesaemia are risk factors for new‐onset atrial 
fibrillation.
48
 Chloride plays a role in renal salt sensing, neurohormonal activation, and regulation of 
diuretic targets, and hypochloraemia predicts mortality in acute and chronic heart failure.
49
 
Markers of kidney function 
The optimal measurement of renal function is uncertain, particularly in the acute setting and 
interpretation should consider the absolute value as well as the change from baseline. The use of serum 
creatinine to estimate glomerular filtration rate (eGFR), which is only one of the three major aspects of 
kidney physiology (filtration, absorption, secretion) has known limitations (e.g. imprecision in non‐steady 
state situations, influenced by muscle mass, tubular secretion affected by certain drugs, influenced by 
diet),
50,51 
but it remains the standard in most hospitals. Measuring serum creatinine is inexpensive, and 
studies of other renal markers (e.g. cystatin C, neutrophil gelatinase‐associated lipocalin) have not 
generated sufficient evidence of superiority over repetitive serum creatinine measurements.  
 
Frequent, most often daily, monitoring of renal function is recommended by the current guidelines 
when intravenous treatments are administered or when renin–angiotensin–aldosterone system antagonists 
are initiated (class I, level of evidence C; Table 1), although guidelines do not give specific 
recommendations for responding to these measurements (Table 3).
6
 Importantly, decreases in eGFR most 
often occur during the first days of hospitalization, which suggests they are caused either by administered 
treatments or were secondary to congestion and already in the process of worsening before admission.
52,53
 
Decongestion can result in either improvement or worsening of renal function, such as an initial 
improvement followed by decline or vice versa. Worsening renal function is associated with poor 
outcome both in acute and chronic heart failure.
54
 Importantly, small (<15–20%) changes in eGFR can be 
accepted if the patient is effectively being decongested, a concept based on recent data that suggest such 
changes are not associated with worse outcome.
55,56
 Additionally, most of the changes observed are 
related to alterations in intraglomerular haemodynamics that result from differences in the tonus of the 
afferent and efferent glomerular arterioles and are not linked with adverse outcomes.
57
 However, in the 
case of worsening eGFR, decreasing urinary output, and persistent congestion, further actions need to be 
taken.
57
 Congestion is an important driver of worsening renal function and, as outlined previously, also 
related to worse prognosis.  
  
Table 3. Potential use of biomarkers in acute heart failure 
Potential clinical 
use 
Biomarkers 
Evidence 
level* 
Current role in clinical practice Limitations 
     
Diagnosis of 
AHF 
NPs Level 1 Well established, recommended† NPs also influenced by age, 
obesity, renal function, atrial 
fibrillation, concomitant 
medications (e.g. ARNI and 
BNP)  
Diagnosis of 
concomitant 
diseases 
Infection (CRP, WBC, PCT) Level 3 Well established, recommended†  
 Renal dysfunction (creatinine, 
urea, others) 
Level 3 Well established, recommended†  
 Anaemia (Hb, ferritin, 
transferrin saturation) 
Level 3 Well established, recommended†  
 Liver function (AST, ALT, 
alkaline phosphatase, GGT, 
INR), lactate 
Level 3 Well established, recommended†  
Risk stratification Many biomarkers (e.g. NPs, 
MR‐proADM, troponins, sST2, 
GDF‐15, renal markers, multi‐
markers) 
Level 4 NP and troponin generally available; 
other markers have limited clinical 
availability in some locations; risk 
scores should be applied when 
available  
Useful for assessing prognosis, 
but lack of evidence that 
biomarkers facilitate clinical 
actions that improve outcome  
Select treatment 
or predict 
response to 
treatment 
PCT for use of antibiotics in 
AHF 
Level 3 Currently investigational Limited evidence, prospective 
study ongoing 
Determine 
treatment effects 
NPs, lactate, sST2, 
haemoconcentration 
Level 4 No general recommendation Treatment‐induced changes in 
biomarkers not yet directly 
linked to clinical outcome 
Monitor safety Renal function, liver function Level 5 Highly recommended†, but expert 
opinion only. No recommendations 
on how to act based on biomarker(s)  
Current renal function markers 
(i.e. SCr) do not adequately 
reflect changing eGFR in acute 
settings  
Monitor post‐
discharge 
outcome 
NPs Level 4 Recommended† to measure at 
discharge, but clinical consequences 
unclear  
NPs also influenced by age, 
obesity, renal function, atrial 
fibrillation, concomitant 
medications (e.g. ARNI and 
BNP)  
Other biomarkers such as sST2, 
Gal‐3, GDF‐15 
Level 5 Limited clinical availability in some 
locations or investigational 
 
     
 
AHF, acute heart failure; ALT, alanine aminotransferase; ARNI, angiotensin receptor–neprilysin inhibitor; AST, aspartate 
aminotransferase; BNP, B‐type natriuretic peptide; CRP, C‐reactive protein; eGFR, estimated glomerular filtrate rate; GGT, 
gamma‐glutamyl transferase; Gal‐3, galectin‐3; GDF‐15, growth differentiation factor‐15; Hb, haemoglobin; INR, 
international normalized ratio; MR‐proADM, mid‐regional pro‐adrenomedullin; NP, natriuretic peptide; PCT, procalcitonin; 
SCr, serum creatinine; sST2, soluble ST2; WBC, white blood cells.  
* Level 1: different prospective studies showing that biomarker(s) change management of patients with positive effect on 
outcome.  
Level 2: one prospective study showing that biomarkers may change management with positive effect on outcome.  
Level 3: retrospective studies suggesting that biomarker may change management, but not yet prospectively tested.  
Level 4: different prospective studies showing positive findings, but no consequences of changes in therapy/management 
tested.  
Level 5: retrospective studies only/limited results with no impact on management/therapy. 
† Recommended by the authors.  
 
 
  
Markers of liver function 
Liver function tests should be performed on admission in accordance with current guidelines (class I, 
level of evidence C).
6
 Liver dysfunction in AHF is most commonly the result of elevated central venous 
pressure and manifested by increases in alkaline phosphatase and gamma‐glutamyl transferase58 or total 
bilirubin;
59
 these abnormalities often improve with decongestion. Elevated transaminases occur with 
hypoxic liver injury in the setting of hypoperfusion, which is less common, but associated with worse 
outcome.
13
 Alternative causes for liver dysfunction should be sought if liver function tests do not 
normalize after decongestion has been achieved and perfusion corrected.  
Cardiac biomarkers 
Cardiac biomarkers are evidence‐based tools for the diagnosis of AHF and determining prognosis. 
The utility of biomarkers to predict response to therapy, determine treatment effects, and monitor changes 
in disease processes or organ‐specific function over time is an area of intense interest and research (Table 
3
). Recently, recommendations for their use was discussed by the American Heart Association,
60 
but 
definitive evidence of their role in clinical practice for these purposes has not been confirmed.
61
 
Natriuretic peptides 
The ESC guidelines recommend measuring a natriuretic peptide level at admission for all patients 
with acute dyspnoea and suspected AHF. This recommendation is based on a strong body of evidence 
(class I, level of evidence A; Table 1).
6
 Clinicians should be aware of factors that can confound 
interpretation of natriuretic peptide values (e.g. renal impairment, atrial fibrillation, other co‐morbidities, 
age, obesity). Pre‐discharge natriuretic peptide levels are also useful for prognosis,6 and pre‐discharge 
levels have demonstrated stronger prediction of post‐discharge outcomes than admission levels.62-64 Thus, 
pre‐discharge assessment of natriuretic peptides may be informative in determining readiness for 
discharge since a reduction of natriuretic peptide levels after decongestive therapy portends a better 
prognosis, but it has not yet been tested if this approach causally improves outcome and therefore it is not 
a specific guideline recommendation. A >30% decrease in N‐terminal pro B‐type natriuretic peptide (NT‐
proBNP) from admission was associated with a lower risk of subsequent death or readmission compared 
to patients without this threshold NT‐proBNP decrease.65 In patients who, based on the clinician's 
judgment, fail to adequately reduce BNP, a more intensified follow‐up might be warranted.  
 
While using natriuretic peptide levels to guide treatment is of substantial interest, it has not improved 
clinical outcomes compared to standard care in randomized studies to date;
66
 most guided studies have 
been in the setting of chronic heart failure. In some randomized trials evaluating treatments for AHF, 
natriuretic peptide and other biomarker profiles improved after treatment with the agent under study, but 
long‐term outcomes were not improved. For example, despite favourable effects on biomarkers, patient 
outcomes were not improved in the SURVIVE (Survival of Patients with Acute Heart Failure in Need of 
Intravenous Inotropic Support),
67
 RELAX‐AHF‐2 (Relaxin in Acute Heart Failure‐2),68 or TRUE‐AHF 
(Trial of Ularitide Efficacy and Safety in Acute Heart Failure)
69
 trials. Post‐hoc analyses have shown an 
association between decreasing natriuretic peptide levels during an admission for AHF and all‐cause 
mortality after multivariate adjustment that included treatment allocation.
70
 These findings provide more 
evidence that clinical outcomes in AHF are influenced by multiple pathways, some of which may not be 
primarily related to heart failure, and natriuretic peptides alone do not appear to sufficiently reflect all 
relevant processes that contribute to mortality.  
  
Cardiac troponin 
Cardiac troponin obtained at admission in patients with AHF (class I, level of evidence C) is useful to 
evaluate the possibility of acute coronary syndrome as a precipitating factor,
6,71
 but a dynamic change 
pattern should be observed to confirm the acute myocardial infarction diagnosis according to current 
acute coronary syndrome guidelines.
72
 The majority of patients presenting with AHF will have elevated 
cardiac troponin levels, and although elevated cardiac troponin is associated with adverse prognosis,6 it 
does not necessarily indicate an acute coronary event if other criteria for acute myocardial infarction are 
absent. Current evidence therefore does not support the role for serial cardiac troponin monitoring in 
patients with AHF without an acute coronary syndrome.  
Other innovative markers 
Many new biomarkers have emerged in the field of AHF, but several studies have suffered from 
inadequate or poorly described methods, optimistically interpreted results, publication bias, and mixing of 
opinion vs. fact.
73
 Thus, guideline recommendations have not yet been made regarding their use, but 
future studies should determine their role. Even more importantly, no study has tested specific strategies 
for altering AHF treatment based on biomarker profiles.  
 
Most biomarker studies in AHF have investigated the prognostic value of single biomarkers, but the 
MOCA (Multinational Observational Cohort on Acute heart failure) study showed that dual biomarker 
combinations improved risk stratification over a single biomarker for 30‐day [C‐reactive protein (CRP) in 
combination with mid‐regional pro‐adrenomedullin, soluble ST2 (sST2), or NT‐proBNP] and 1‐year 
survival (CRP and sST2 reclassified risk to the greatest extent).
74
 Similar improvements in 
prognostication using combined biomarkers have been demonstrated in other studies.
75
 However, use of 
these biomarker panels in clinical practice will depend on their routine availability.  
 
The detection of important co‐morbidities is a promising application for biomarkers in patients with 
AHF, not only for risk assessment but primarily to assess the need for treatment of co‐morbidities (e.g. 
detection of bacterial infection such as pneumonia). Procalcitonin is more specific for infection than other 
inflammatory markers (e.g. CRP), and retrospective data suggest that both untreated bacterial infection 
and unnecessary antibiotic treatment in AHF are associated with worse outcome.
76
 IMPACT‐EU 
(Improve Management of Heart Failure with Procalcitonin, NCT02392689) is an ongoing prospective 
study of the effect of procalcitonin‐guided antibiotic therapy vs. physician‐determined antibiotic therapy 
on the primary endpoint of 90‐day all‐cause mortality. If effective, this approach would be one of the first 
proven biomarker‐guided treatment approaches in AHF.  
Electrocardiography and telemetry 
Rhythm disturbances and ischaemia may be a primary cause of an AHF episode.
77
 Conversely, 
haemodynamic instability may give rise to arrhythmias, or these may be iatrogenic in origin (e.g. 
secondary to inotrope or vasopressor administration).  
 
Obtaining an electrocardiogram (ECG) during the initial evaluation is routine practice (class I, level of 
evidence C).
6
 Telemetry monitoring is recommended by the American Heart Association in all patients 
with AHF who are at significant risk of an immediate, life‐threatening arrhythmia and should be 
continued until the patient is stabilized.
78
 Telemetry monitoring may also help with detecting episodes of 
ischaemia. Patients hospitalized for AHF commonly have multiple co‐morbidities, and telemetry 
monitoring may be recommended with concomitant conditions such as acute respiratory failure, shock, 
acute pulmonary embolus, or renal failure with electrolyte abnormalities (e.g. hyperkalaemia) where the 
risk of arrhythmia is increased. It is also recommended in patients on inotropic support.  
  
Telemetry monitoring is presumed to improve patient safety, but there is no definitive evidence that it 
improves patient outcomes.
79-81
 Continuous telemetry beds are increasingly available in many hospitals. 
Risk stratification tools to detect high‐risk patients and specific protocols for them may be helpful to 
triage which patients need telemetry to ensure efficient resource utilization since continuously monitoring 
all patients with AHF may be inappropriate and not cost‐effective.  
Imaging 
Chest X‐ray 
Chest X‐ray can be an informative test in the evaluation of patients with suspected AHF, but its main 
utility is in identifying alternate causes for the patients' symptoms. Pulmonary venous congestion, pleural 
effusion, interstitial or alveolar oedema and cardiomegaly are the most specific findings for AHF.
82,83
 
However, up to 20% of patients with AHF will have no or little congestion visible on their emergency 
department chest radiograph;
84
 thus, chest X‐ray alone cannot rule out AHF. Supine chest radiographs 
have limited value in the evaluation of patients with AHF.
85,86
 A chest X‐ray is recommended at 
admission in patients with suspected AHF (class I, level of evidence C). To avoid unnecessary irradiation, 
serial chest X‐rays are not routinely recommended.87 Evidence is lacking to support monitoring patients 
with AHF by chest X‐ray, and few data are available comparing chest X‐ray to other clinical and 
haemodynamic tools. There is old evidence from patients with chronic cardiomyopathy showing 
decreasing wedge pressure
88
 as well as clinical improvement
86
 before remission of chest X‐ray findings. 
Repeat chest X‐rays should be reserved for patients with a clearly worsening clinical condition or in 
whom concurrent pulmonary diseases are suspected.
6
 Other imaging modalities (e.g. lung ultrasound) 
may be used as an alternative to repeat chest X‐ray to assess congestion or diagnose pleural effusions.89 
 
Distinguishing between pulmonary oedema and acute respiratory distress syndrome is one of the most 
challenging differential diagnoses in the emergency department and the ICU.
90
 Cardiogenic pulmonary 
oedema is the main radiographic differential diagnosis, but acute respiratory distress syndrome is 
favoured when cardiomegaly, septal lines, or pleural fluid are absent, and peripheral alveolar opacities are 
present.
91
 The Berlin definition of acute respiratory distress syndrome consists of timing, chest imaging 
(chest X‐ray or computed tomography scan), origin of oedema, and degree of oxygenation.92 In practice, 
acute respiratory distress syndrome and cardiogenic pulmonary oedema can coexist. Discrimination 
between the two is often difficult using chest radiography alone, but it may be improved by 
echocardiography to detect cardiac failure.
91,93
 
Echocardiography 
Specific guideline recommendations for the use of echocardiography in AHF are provided in Table 1. 
Echocardiography may also be useful for monitoring filling pressure and cardiac output; research 
supporting this role is further described below. The value of strain imaging in the monitoring of AHF 
requires further research.  
Echocardiography for monitoring filling pressures 
There is little evidence to date of either clinical utility or diagnostic accuracy of Doppler 
echocardiography indices for monitoring left ventricular filling pressures in the setting of AHF. Only a 
few studies simultaneously performed invasive and non‐invasive estimation of left ventricular filling 
pressures.
94-98 
  
The American Society of Echocardiography (ASE) and the European Association of Cardiovascular 
Imaging (EACVI) proposed an algorithm for estimating mean left atrial pressure based on a 
comprehensive assessment of diastolic indices (Table 4).
99
 It was originally based on expert consensus 
but recently has been validated in a multicentre European study against invasive measurement of left 
ventricular filling pressure.
100
 Solely assessing mitral annular velocities is poorly correlated with left 
ventricular filling pressures in several clinical scenarios (e.g. patients with coronary artery disease which 
affected basal septal or lateral segments, significant mitral annular calcification, surgical rings or 
prosthetic mitral valves, left bundle branch block, right ventricular pacing, cardiac resynchronization 
therapy, and pericardial disease).
99
 Several studies have also challenged the utility of E/e′ ratio for 
estimation of pulmonary capillary occluded pressure in patients with advanced or decompensated heart 
failure with reduced ejection fraction.
98,101
 
Table 4. Echocardiography parameters to estimate cardiac pressures 
Parameter and findings Interpretation 
  
For estimation of LAP  
E/A ratio <0.8 
Peak E velocity ≤50 cm/s99 
Normal or low 
E/A ratio ≥2 
Deceleration time <160 ms (in patients with 
reduced LVEF)99 
Elevated LAP 
Average E/e′ <899 Normal or low LAP 
Average E/e′ >1499 Elevated LAP 
Increased systolic and diastolic PAP estimated by 
CW Doppler TR systolic jet velocity 
Elevated in approximately 70% of HF cases157 (match of left and right); can also 
be encountered in normal or low LAP  
E/A ratio >0.8 and <299 Recommended assessment of peak velocity of TR jet by CW Doppler, E/e' ratio, 
and LA volume index for accurate evaluation  
For estimation of RAP  
IVC <2.1 cm that collapses >50% with a sudden 
inspiratory manoeuvre (i.e. sniff)158 
Suggests normal RAP of 3 mmHg (range 0–5 mmHg)158 
IVC diameter >2.1 cm that collapses <50% with a 
sniff158 
Suggests high RAP of 15 mmHg (range 10–20 mmHg)158 
Scenarios in which IVC diameter and collapse do 
not fit the above paradigms158 
An intermediate value of 8 mmHg (range 5–10 mmHg) may be used or, 
preferably, other indices of RAP should be integrated to downgrade or upgrade 
to the normal or high values of RAP158 
IVC ≤12 mm (in patients with positive pressure 
ventilation degree of IVC collapse cannot be 
used)159 
RAP <10 mmHg159 
Hepatic vein flow pattern Vs >Vd (systolic 
predominance in hepatic vein flow)158 
Low or normal RAP160 
Hepatic vein systolic filling fraction (VTIs/VTIs + 
VTId) <55%160 or Vs/Vd <1158 (lost systolic 
predominance)  
Elevated RAP160 
  
 
CVP, central venous pressure; CW, continuous wave; HF, heart failure; IVC, inferior vena cava; LAP, left atrial pressure; LV, left 
ventricular; LVEF, left ventricular ejection fraction; PAP, pulmonary artery pressure; RAP, right atrial pressure; TR, tricuspid 
regurgitation; Vd, diastolic wave; Vs, systolic wave; VTI, velocity–time integral. 
 
  
Despite these limitations, recent ASE guidelines favour the use of comprehensive echocardiography 
assessment to monitor therapeutic interventions and indicate that mitral inflow velocities and E/e′ are 
reliable indices of left atrial pressure.
102
 Besides, indices of diastolic dysfunction may reflect pathogenic 
mechanisms related to vascular and cardiac stiffness independent of filling pressures.
103
 In the setting of 
atrial fibrillation, a recent review showed that diastolic parameters such as E/e′, isovolumetric relaxation 
time, and E/Vp correlated with invasive filling pressure and demonstrated adequate reproducibility. For 
optimal acquisition in atrial fibrillation patients, cardiac cycles with controlled heart rate (<100 b.p.m.) 
and similar preceding and pre‐preceding RR intervals are required.104 A restrictive mitral inflow pattern 
on Doppler echocardiography had a diagnostic accuracy for heart failure of 91% in patients hospitalized 
with acute dyspnoea.
105
 Repeat Doppler examination after initiation of diuretic and vasodilator therapy 
and clinical improvement often showed markedly different findings from baseline,
105
 suggesting that it 
might be a tool to monitor response to therapy. In a single‐centre study of 60 patients, the significant 
decrease in E/e′ was observed as early as within the first 12 h of treatment with further decline during 
48 h, contrary to the delayed response of inferior vena cava (IVC) and BNP values.106 Change in 
pulmonary capillary occluded pressure was strongly correlated with change in E/e′ at 48 h but not with 
BNP in 50 patients admitted to intensive care,
94
 although many factors other than left atrial pressure can 
affect BNP levels. Non‐invasive indices should be used cautiously in patients with heart failure with 
preserved ejection fraction because of the high variability of individual linear regression slopes relating 
E/e′ and E/Vp with invasive measures. Nevertheless, these indices have been useful to identify a cardiac 
source in patients who fail to wean from mechanical ventilation.
107,108
 Importantly, filling pressures do not 
always correlate with volume overload; thus, diuretic therapy cannot solely be guided by 
echocardiographic examination.
6,109 
 
Inferior vena cava diameter and respiratory variation can be used to estimate right atrial pressure, 
being similarly altered in heart failure with reduced or preserved ejection fraction
7
 (Table 4). In patients 
with advanced heart failure, echocardiographic right atrial pressure prediction methods showed modest 
precision; a single IVC diameter measurement was non‐inferior to complex prediction methods.110 
Nagueh et al.
95
 also demonstrated a strong correlation between invasive and non‐invasive estimates of 
mean right atrial pressure in patients with acute decompensated heart failure. A recent systematic 
review
111
 showed that the diagnostic accuracy of IVC measurement parameters was generally high, with 
the C‐statistic ranging from 0.76–0.91 for IVC diameter and 0.66–0.93 for IVC collapsibility index.111 
The novel 3D echocardiography right atrial volume index has been proposed and validated in conjunction 
with IVC diameter as having an incremental value for detection of elevated right atrial pressure in 
patients with AHF.
112 
Interestingly, assessment of renal venous flow might be an emerging technique to 
assess early changes in renal response to volume overload before overt congestion is evident.
113
 The 
reasonable diagnostic performance of pre‐specified cut‐points justifies the current guideline 
recommendations
99 
for using IVC diameter to estimate right‐sided filling pressure.  
Echocardiography for monitoring cardiac output 
Echocardiography is capable of monitoring cardiac output, although discontinuously, using pulsed‐
wave Doppler in the left ventricular outflow tract. Either transthoracic or transoesophageal 
echocardiography may be used to estimate cardiac output. However, few studies have validated the 
accuracy of echocardiography compared to the ‘gold standard’ pulmonary artery catheter (PAC).114 One 
recent study in 38 mechanically ventilated patients found high correlation (r=0.95) between cardiac 
output measured by PAC and cardiac output measured by transthoracic echocardiography.
115
 The 
techniques are not interchangeable when measuring cardiac output, but they may be interchangeable to 
follow directional changes in cardiac output.
114 
 
Echocardiography has been strongly recommended by consensus groups in patients presenting with 
circulatory failure.
116,117
 It should be noted that echocardiography allows performance of the full 
haemodynamic evaluation, including chamber volumes, systolic and diastolic function, and heart–lung 
interactions, filling pressure, and cardiac output.  
  
Lung ultrasound 
Lung ultrasound can be performed at the bedside using portable devices; thus, its application to both 
general medicine and emergency or intensive settings has expanded considerably. The performance of 
lung ultrasound is better than chest X‐ray to rule out interstitial and alveolar oedema.89,118 
 
Many aetiologies are possible in patients presenting with acute dyspnoea. Lung ultrasound can stratify 
patients according to the likely underlying pathology based on visualization of B‐lines.89 B‐lines are an 
important and reliable marker of pulmonary congestion, but it is difficult to identify the source of 
pulmonary oedema (hydrostatic or non‐hydrostatic) with lung ultrasound alone. Pleural effusion is also 
reliably detected with lung ultrasound, with good performance and a better detection threshold than chest 
X‐ray. The combination of lung ultrasound and point‐of‐care natriuretic peptide testing may be helpful in 
the immediate evaluation of patients with dyspnoea in the emergency department.
119
 Lung ultrasound is 
helpful to differentiate cardiac vs. non‐cardiac causes of acute dyspnoea in the emergency department.120 
B‐lines appear to be dynamic in nature, as they decrease in proportion to the amount of fluid removed in 
patients undergoing dialysis.
121
 They have also been shown to decrease with treatment of AHF.
106,122-124 
According to a recent systematic review, B‐line number changed within as few as 3 h of heart failure 
treatment.
123 
However, the number of studies and sample sizes were small and investigator blinding was 
inadequate.
123
 
Invasive monitoring 
Arterial, central venous, and pulmonary artery catheters 
The ESC guidelines recommend the insertion of an arterial line in patients with AHF and clinical 
evidence of cardiogenic shock (class I, level of evidence C; Table 1).
6
 The arterial line allows for 
repetitive sampling of arterial blood gases, providing important information on oxygenation (PaO2), 
ventilation (PaCO2), acid–base balance, electrolytes and lactate levels.
17
 The continuous measurement of 
arterial pressure allows for the appropriate titration of vasoactive medication, if needed. Respiratory 
variations of invasive arterial pressure might indicate, among others, right ventricular failure or 
pericardial tamponade.  
 
The central venous catheter enables the monitoring of central venous pressure and allows the safe and 
continuous administration of vasoactive drugs and inotropes in patients with AHF who require intensive 
treatment. Central venous oxygen saturation (ScvO2) can also be monitored with the central venous 
catheter.
125
 ScvO2 declines when oxygen delivery decreases and, particularly in patients with AHF, when 
cardiac output deteriorates. In combination with increased lactate levels and signs of organ dysfunction, a 
ScvO2 <60% indicates severe hypoperfusion and mandates further diagnostics and urgent treatment.  
 
There is no agreement on the optimal method of extended haemodynamic monitoring in assessing and 
treating the patient in cardiogenic shock.
17
 One option is the PAC, i.e. Swan–Ganz catheter. A PAC may 
be considered in patients who, despite pharmacological treatment, present with refractory symptoms, 
particularly with hypotension and hypoperfusion (Table 1).
6
 However, data from the PAC‐Man 
(Pulmonary Artery Catheters in Management of Patients in Intensive Care) study did not support either 
benefit or harm from use of a PAC in critically ill patients (decompensated heart failure 11% of the 
population).
126
 Furthermore, the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary 
Artery Catheterization Effectiveness) trial in patients hospitalized for decompensated heart failure but not 
in cardiogenic shock showed that though the rate of effective decongestion was increased, the use of a 
PAC did not impact the number of days alive and out of the hospital at 6 months, but it was associated 
with more adverse events.
127
 Based on these data and the imbalance between potential benefits and known 
risks, PAC should not routinely be used to monitor patients with AHF, but it can still be justified to use 
PAC in selected populations. PAC is most appropriately used by experienced physicians in clinically 
compromised situations, where rapid evaluation of vasoactive medications or fluid balance is needed.   
Risk scores 
Risk scores can be useful to identify the lowest risk patients who could safely be managed in an 
observation unit or discharged and followed in the outpatient setting in contrast to identifying high‐risk 
patients who require hospital admission and to determine prognosis.
128,129
 Most risk scores were designed 
to estimate high risk, but low risk is not always simply the inverse of high risk. Calculating low risk to 
some extent is more useful than calculating high risk, as low‐risk patients may be safely discharged, 
saving expensive hospital admission.
130
 The same concept applies to hospitalized patients, in order to get 
a better selection of the best moment for hospital discharge to minimize the risk of rehospitalization.  
 
Clearly, risk scores must be developed in patient cohorts matching the setting where they will be 
applied, as they are not interchangeable. A recent review found 11 risk scores (nine for hospitalized 
patients and two for emergency department patients) that could be applied in patients with AHF.
131 
Two 
additional scores for use in the emergency department have subsequently been developed.
132,133
 Although 
some of these risk scores reached promising high discriminatory capacity (C‐statistic for EHMRG risk 
score 0.807; C‐statistic for MEESSI‐AHF risk score 0.836), none have been sufficiently validated or 
prospectively tested to support widespread use.
129
 
Role of nursing in clinical monitoring 
Nurses are involved across the continuum of care from early identification of AHF or decompensated 
heart failure symptoms, to monitoring the patient's response to therapeutic intervention,
17 
early facilitated 
discharge,
134
 and prompt community follow‐up.135 As key members of the multidisciplinary team, they 
are responsible for the 24 h monitoring of patients admitted with AHF ensuring effective communication 
among professionals as well as education and support to patients and caregivers. Over recent years, 
evidence has shown the value of nurse‐led interventions, in terms of improved survival and quality of life 
as well as reduced length of hospital stay and rates of readmission.
17,136-138
 Reviewing patients during the 
critical post‐discharge phase (7–14 days) enables evaluation of clinical status and patient's self‐
management behaviours.  
Potential future monitoring applications 
Non‐invasive haemodynamic monitoring 
The complications associated with invasive monitoring (e.g. mechanical complications and infectious 
risks) have contributed to the development of non‐invasive technologies. Non‐invasive techniques are 
undergoing considerable development, although none can be currently recommended for routine clinical 
use. Invasive techniques such as the PAC and transpulmonary thermodilution remain the reference 
standard.  
Contour of the pulse wave 
Several algorithms have been proposed to determine cardiac output based on determination of systolic 
area by analysis of the contour of the pulse wave.
139
 In most cases, these signals are obtained from an 
arterial line. The system may be calibrated (by transpulmonary thermodilution or lithium dilution) or not. 
Some of the non‐calibrated systems estimate arterial elastance and vascular tone.140 
  
Digital photoplethysmography 
Digital photoplethysmography is a technique for continuous measurement of blood volume 
changes.
141,142
 Severe skin vasoconstriction, which is common in cardiogenic shock, impairs signal 
quality of blood pressure and is an important limitation of the technique. These monitors are not useful 
when arterial impedance is variable, such as with vasoconstrictor administration, unless given 
continuously and steady state has been reached. Digital photoplethysmography techniques do not appear 
to be sufficiently effective in assessing cardiac output in resuscitation patients with microcirculatory 
disorders, peripheral vasoconstriction, or high blood pressure lability.
143,144
 
Thoracic bioimpedance 
Transthoracic electric bioimpedance, also called impedance plethysmography or impedance 
cardiography, is a non‐invasive method for measuring cardiac output.145 Several haemodynamic 
parameters can be measured and calculated using the technique including flow (e.g. stroke volume/stroke 
index), resistance (e.g. systemic vascular resistance/index), contractility (e.g. cardiac power index, 
systolic time ratio, pre‐ejection period, left ventricular ejection time, velocity index, acceleration index), 
and fluid (e.g. thoracic fluid content).
146-148 
 
Thoracic bioimpedance data may be informative in several clinical contexts, such as fluid 
management in patients with AHF,
146,149
 and the differentiation of cardiogenic from pulmonary causes of 
acute dyspnoea, among others.
150
 Bioimpedance might be useful for trend analysis, but the data should be 
interpreted cautiously, as the method is associated with limitations that may affect its accuracy (e.g. 
diseases of the aortic valve or aorta, arrhythmias, acute changes in tissue water such as pulmonary or 
chest wall oedema or pleural effusion, mechanical ventilation, body motion, and factors that affect 
conductivity between the electrodes and the skin like temperature and humidity).
147,151-153 
 
Bioreactance has a higher signal‐to‐noise ratio,145,148 and initial validation studies revealed promising 
results in different clinical settings.
154
 Currently available data are insufficient to support guideline 
recommendations for use of bioimpedance and bioreactance in the routine monitoring of patients with 
AHF, although new systems show potential promise.  
Videomicroscopy 
Microvascular perfusion can be directly assessed by videomicroscopic techniques, mostly applied 
sublingually, although these are employed more often as research tools and are not widely applicable in 
routine clinical practice. Microcirculatory perfusion is altered in patients with AHF and cardiogenic 
shock.
155
 Alterations in microvascular perfusion are more severe in non‐survivors.155,156 More 
importantly, changes over time also differ between survivors and non‐survivors. Sublingual perfused 
capillary density may be an effective tool to measure tissue microvascular perfusion and estimate 
prognosis.
156
 Measurements of veno–arterial pCO2 differences may be an interesting surrogate.
39
 
Conclusion 
Many tools are available for the in‐hospital monitoring of patients with AHF, and each may play a 
role at various points throughout the patient's treatment course (Table 5, Figure 1). At present, clinical 
judgment guides the application of many of these tools. Physicians must set goals for monitored variables 
and tailor management according to their comprehensive interpretation of acquired clinical, biochemical, 
haemodynamic, and physiologic patient data. Future research initiatives should aim to identify the 
optimal in‐hospital monitoring strategies for patients with AHF that reduce morbidity, prolong survival 
and are safe and cost‐effective.  
  
Table 5. Use of monitoring across points of care delivery 
 
Emergency department 
Intensive care unit/coronary 
care unit 
General ward 
    
Patient population All patients Cardiogenic shock; pulmonary 
oedema 
Congestive heart failure/‘wet 
and warm’ 
Non‐invasive vital 
sign monitoring 
At initial presentation and regularly during 
ED stay (blood pressure, heart rate, 
respiratory rate, pulse oximetry)  
See haemodynamic monitoring 
(continuous blood pressure, 
respiratory rate monitoring) 
Ideally three times daily, but at 
a minimum once daily (blood 
pressure, respiratory rate, pulse 
oximetry)  
Body weight On admission if possible/available Daily when possible (requires 
specific bed with a scale) 
Daily 
Urine output/fluid 
balance 
Check response to first dose of diuretic in 
the ED 
Daily monitoring of net fluid 
balance 
When indicated; urinary 
catheter not recommended 
Blood gases and 
lactate 
See ICU/coronary care unit 
recommendation 
On admission to ICU and every 
1–2 h during acute phase, then 
decrease frequency 
As indicated by clinical 
situation and co‐morbidities 
Electrolytes and 
markers of renal 
function 
All patients Daily or more often if clinically 
indicated 
Every 1–2 days until discharge 
Complete blood 
count 
All patients As indicated by clinical 
situation and co‐morbidities 
As indicated by clinical 
situation and co‐morbidities 
Liver function All patients As indicated after decongestion 
achieved 
As indicated by clinical 
situation and co‐morbidities 
Cardiac biomarkers NP and cTn 
ST2 may be considered 
cTn only to evaluate for 
suspected AMI 
NP may be considered pre‐
discharge 
Procalcitonin On admission 
Procalcitonin may be useful in patients with 
suspected coexisting infection 
As indicated by clinical 
situation and co‐morbidities 
As indicated by clinical 
situation and co‐morbidities 
ECG and telemetry 
monitoring 
ECG on admission, telemetry in selected 
cases 
All Continuous telemetry in 
selected cases 
Chest X‐ray On admission Only as needed Only as needed 
Echocardiography Immediate echocardiography in patients 
with haemodynamic instability (cardiogenic 
shock) and in patients suspected of acute 
life‐threatening structural or functional 
cardiac abnormalities  
Upon ICU admission (unless 
direct admission from ED) and 
repeated as needed 
Early (preferably within 48 h of 
admission) in de novo patients 
and those with unknown 
cardiac function.  
Repeated echocardiogram not 
needed unless relevant 
deterioration (or lack of 
improvement) in clinical status  
Lung ultrasound Lung ultrasound if available As indicated by clinical 
situation and co‐morbidities; 
assessment of decongestion 
As indicated by clinical 
situation and co‐morbidities; 
assessment of decongestion 
Haemodynamic 
monitoring 
Non‐invasive measurements of blood 
pressure 
Invasive blood pressure; CVC; 
cardiac output monitoring 
(various devices); PAC in 
selected patients in cardiogenic 
shock  
N/A 
    
 
AMI, acute myocardial infarction; cTn, cardiac troponin; CVC, central venous catheter; ECG, electrocardiogram; ED, emergency 
department; ICU, intensive care unit; N/A, not applicable; NP, natriuretic peptide; PAC, pulmonary artery catheter. 
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